• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Xeris Pharmaceuticals kicks off dual-hormone artificial pancreas trial

August 20, 2018 By Sarah Faulkner

Xeris PharmaceuticalsXeris Pharmaceuticals (NSDQ:XERS) said last week that it launched a Phase I trial of its ready-to-use liquid glucagon in a closed-loop, dual-hormone artificial pancreas system.

Automated insulin delivery systems represent the latest advancement in diabetes management. But these technologies fall short of performing the tasks of a human pancreas – they deliver insulin, but they can’t co-deliver glucagon. Traditional dry-powder glucagon formulations must be used immediately, according to Xeris, or else they begin to degrade.

The Chicago-based company has developed a glucagon formulation that is stable at room temperature over extended periods of time. A closed-loop system that can deliver both glucagon and insulin could help reduce a user’s risk of hypoglycemia, Xeris explained, since the system would behave similarly to the body’s natural methods of glucose control.

The Phase I trial, designed to test the efficacy of a closed-loop algorithm in people with Type I diabetes before and after exercise, will be conducted by Dr. Jessica Castle at the OHSU School of Medicine and OHSU Harold Schnitzer Diabetes Health Center.

Researchers plan to compare a dual-hormone artificial pancreas using Xeris’ glucagon with a single-hormone artificial pancreas and a low-glucose suspend algorithm. Xeris said that it expects results from the study in the first half of 2019.

“The goal in researching our liquid stable glucagon formulation as part of a dual-hormone closed-loop mated system is to overcome the limitations of current dry-powder glucagon formulations in automated pump systems to manage diabetes; this trial will help us better understand the potential application of our ready-to-use glucagon formulation,” chairman & CEO Paul Edick said in prepared remarks. “Our research collaboration with OHSU and JDRF is an important opportunity to determine how a dual-hormone artificial pancreas may help advance the standard of care for people with diabetes.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: xerispharmaceuticals

IN CASE YOU MISSED IT

  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor
  • Mosanna launches with $80M to support nasal spray for obstructive sleep apnea

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS